Multiple studies have shown that KRAS is the most common mutant oncogene in NSCLC, and KRAS mutant lung cancer has a poor prognosis and is resistant to chemotherapy; in addition, in the presence of this mutation, patients are more likely to have liver and brain metastasis [62–64]. This evidence concerns the gene KRAS and lung carcinoma.